Mr. Speaker, let us look at the global health fund, for example. There are fewer and fewer resources available to cope with the major challenges it must face.
When the global health fund is forced to invest what little it has in buying drugs, this does not leave room for other initiatives. I do not think that we can assume that the savings from drug purchases will automatically be allocated to other infrastructure. However, having access to more affordable drugs will certainly free up resources within the countries and among donors and multilateral organizations and allow them to continue working on other aspects.